Dallas, TX (PRWEB) April 16, 2007
Diabetech, LP, a proven leader and pioneer in active disease management, today announced that Fran Dramis, former Chief Information Officer for BellSouth Corporation (now AT&T), has joined the Diabetech Advisory Board. Mr. Dramis is a telecom industry veteran who brings to Diabetech vast knowledge and experience, having designed, built, and managed some of the largest, most complex, and secure service provider infrastructure in the world.
Mr. Dramis joined BellSouth Corporation in 1998 as CIO and led the IT organization as Chief Information, E-Commerce and Security Officer for the past eight years. Before joining BellSouth, Mr. Dramis worked with CIO Strategy, Inc., an information technology consulting firm. Prior to that time, Mr. Dramis was managing director and CIO at Salomon Brothers. Mr. Dramis also served as president and chief executive officer of Network Management and president and chief operating officer of Telic Corporation. Early in his career, Mr. Dramis worked with AT&T, including Bell Labs, rising to the position of executive director of information product management. In addition to serving on Diabetech's Advisory Board, Mr. Dramis currently serves on the Boards of RealOps, Avocent Corporation and webMethods.
"We're very excited to work with Fran as we develop our employer focused interventional programs," said Kevin McMahon, President & CEO of Diabetech. "Fran clearly understands the potential of technology and appreciates our participant-centric system for delivering just-in-time education with a unique design for enabling team management including support from friends, family, co-workers and their medical team. His first hand experience with this innovative approach will help us to communicate with employers struggling to control health care costs and for their employees, dependents and retirees looking for an innovative program that works."
Fran has been recognized by a variety of publications as a top CIO and IT leader. "As a former CIO, I have witnessed Diabetech's automated diabetes intervention programs in action. By integrating real-time wireless medical devices, rules based decision support and social networks, the long promised yet seldom delivered return on investment from disease management programs is here."
Dave Johnson, President & CEO of Aimbridge Hospitality and a Executive Committee Member of Juvenile Diabetes Research Foundation (JDRF) International brings a combination of business savvy and diabetes-specific insight to the Diabetech Advisory Board. In recent years, Mr. Johnson has helped Aimbridge to become one of the fastest growing hotel management companies in the United States. At the same time, his leadership within JDRF has contributed to the launch of an exciting new track of research focused on the development of an artificial pancreas; a field of research that combines continuous glucose monitoring intelligent insulin dosing through software designed to mimic the body's own metabolic processes.
"My efforts in diabetes are focused on accelerating 'time-to-patient' for innovative cure therapies that mitigate complications for our kids. As the father of a teen with type 1 diabetes, my family has experienced tremendous benefit from use of the Diabetech technology inside of monitored research trials. This is an exciting time for me and for Diabetech as we prepare to make the GlucoMON® wireless glucose meter more accessible to more families looking to simplify the way they manage diabetes", said Johnson.
Before joining Aimbridge, Johnson spent 17 successful years with Wyndham Hotels and Resorts helping them grow from ten hotels to over 200. While at Wyndham, Johnson served as Executive Vice President, President/Chief Marketing Officer, and President of the Hotel Division. Johnson currently serves on several Boards of Directors in addition to JDRF including Meeting Professionals International and Active International. He is on the Board of Governors for the University of North Texas and is a member in good standing of the Chief Executive Round Table (CERT). Johnson was most recently named to Starwood's Real Estate Development Advisory Board. In 2003, he was named as one of the 25 Most Extraordinary Minds in Hospitality Sales & Marketing by HSMAE.
"We're very excited to welcome Dave into the Diabetech family," said McMahon. "His insight and passion for improving the lives of people with diabetes and those who care for them will help us as we prepare to commercialize the GlucoMON later this year. In addition to making sure that families understand the benefits offered by Diabetech, delivering the 'five-star' customer experience will be key to our success."
Other members of the Diabetech Advisory Board representing the medical perspective include Stephen Ponder, MD CDE (pediatric endocrinologist), Barbara Anderson, PhD (diabetes specific behavioral scientist) and Barry Goldstein, MD PhD (adult endocrinologist).
Diabetech evaluates the opportunity to add wireless connectivity, remote device management and field support for the many medical device manufacturers and researchers years ahead of the various emerging standards organizations. In early 2003, Diabetech became the founding member behind Diabet-ML, an open standard for diabetes relevant data integration. Unlike generic wireless network aggregators and cellular device manufacturers, Diabetech applies its intricate knowledge of the wireless networks, the medical device industry and diabetes to seamlessly integrate the design and manufacturing processes as well as making sure that the people depending on this system enjoy simplicity through automation and world class support.
Our wireless medical device certification program offers a turnkey path for transforming disconnected medical devices into favourable outcome generators. Due to significant investment in our wireless data service provider platform, new wireless handheld medical devices can be designed and deployed with patients in the field in weeks without the high cost and delays that go with one-off multi-vendor projects offered elsewhere. Once devices are deployed, feasibility testing and design optimization can be rapidly and cost-effectively performed at a fraction of the cost of any other wireless service provider including 510(k) submission and large scale commercialization of these hybrid devices.
We push the limits of clinical informatics in the delivery of real-world diabetes care. For more information on the company and to participate in our version of proactive care, please visit http://www.diabetech.net or call us toll free at 877.My.Gluco. Interested parties outside of the US should send email to [email protected] to initiate correspondence.
Diabetech and GlucoMON are registered trademarks of Diabetech, LP.
GlucoMON is an investigational device subject to certain FDA guidelines including 510(k) marketing clearance prior to marketing for sale in the US. All other local regulations apply. The performance characteristics of these devices have not been established. This service offering is compliant with applicable federal and state regulations including HIPAA, which govern the privacy and security of human subjects research.
# # #